TwitterFacebookLinkedIn

IGCS 2021 Industry Supported Symposia

 

How Cemiplimab is EMPOWERING change in the management of recurrent cervix cancer

Funded with a grant from Regeneron.

 

Mirvetuximab Soravtansine, an Antibody-Drug Conjugate Targeting the Folate Receptor for Women with Ovarian Cancer

 

New Perspectives in Ovarian Cancer: Current Paradigm and Long-term Benefits of PARPi Therapy

 

Solutions to Address Missed Opportunities for Genetic Testing Globally

 

The Evolution of NGS for Gynecologic Malignancies: Delivering for Future for More Precise Treatment

 

The evolving treatment of landscape of gynecological tumors

Antibody Drug Conjugates in Treating Recurrent Ovarian Cancer: The Next Generation - A Focus on NaPi2b

Platinum-Resistant Ovarian Cancer: Treatment Landscape and Future Opportunities